Literature DB >> 25376624

Platelet-derived growth factor receptor-β expression in human peritoneum.

Harald Seeger1, Niko Braun, Joerg Latus, M Dominik Alscher, Peter Fritz, Ilka Edenhofer, Dagmar Biegger, Maja Lindenmeier, Rudolf P Wüthrich, Stephan Segerer.   

Abstract

INTRODUCTION: Simple peritoneal fibrosis and encapsulating peritoneal sclerosis (EPS) are important lesions in the peritoneum of patients on peritoneal dialysis (PD). We have previously described a population of podoplanin-positive myofibroblasts in peritoneal biopsies from patients with EPS. Platelet-derived growth factor receptor-β (PDGFRβ) is a marker of pericytes, and PDGFs might be involved in the fibrotic response of the peritoneum. This study aimed to describe PDGFRβ in the human peritoneum.
METHODS: In this retrospective analysis, we localized PDGFRβ in peritoneal biopsies from patients with EPS (n = 6) and patients on PD without signs of EPS (n = 5), and compared them with normal peritoneum (n = 4) and peritoneum from uremic patients (n = 5). Consecutive sections were stained for smooth-muscle actin (SMA) and podoplanin. Slides were scored semiquantitatively by 2 observers blinded to the diagnosis.
RESULTS: PDGFRβ was expressed by cells of arterial walls in all biopsies. A prominent population of PDGFRβ-positive cells was present in the normal peritoneum, which were SMA negative on consecutive sections. In patients on PD, a high number of PDGFRβ were also positive for SMA. In EPS, the majority of podoplanin-positive cells were positive for PDGFRβ. In peritoneal biopsies from normal and uremic patients, the expression of SMA was mainly restricted to cells of arterial walls. Podoplanin expression was restricted to lymphatic vessels in normal peritoneum, in uremic patients, and in patients on PD without EPS.
CONCLUSIONS: As podoplanin-positive myofibroblasts express PDGFRβ, these cells might be related to pericytes (rather than other sources of fibroblasts). PDGFRβ might turn out to be a therapeutic target in EPS.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25376624     DOI: 10.1159/000368241

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  5 in total

1.  Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis.

Authors:  Sibel Ada; Sibel Ersan; Aykut Sifil; Mehtat Unlu; Efsun Kolatan; Mehmet Sert; Sulen Sarioglu; Osman Yilmaz; Taner Camsari
Journal:  Int Urol Nephrol       Date:  2015-10-03       Impact factor: 2.370

2.  CD147 expression in peritoneal injury.

Authors:  Harald Seeger; Joerg Latus; Daniel Kitterer; M Dominik Alscher; Dagmar Biegger; Jin Chen; Ilka Edenhofer; Rudolf P Wüthrich; Stephan Segerer
Journal:  Clin Exp Nephrol       Date:  2017-05-27       Impact factor: 2.801

3.  Phenotypically heterogeneous podoplanin-expressing cell populations are associated with the lymphatic vessel growth and fibrogenic responses in the acutely and chronically infarcted myocardium.

Authors:  Maria Cimini; Antonio Cannatá; Gianandrea Pasquinelli; Marcello Rota; Polina Goichberg
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

4.  Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model.

Authors:  Binbin Cui; Chao Yu; Shenglei Zhang; Xiying Hou; Yi Wang; Jun Wang; Shougang Zhuang; Feng Liu
Journal:  Kidney Dis (Basel)       Date:  2022-04-11

Review 5.  New developments in peritoneal fibroblast biology: implications for inflammation and fibrosis in peritoneal dialysis.

Authors:  Janusz Witowski; Edyta Kawka; Andras Rudolf; Achim Jörres
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.